These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 36769308)

  • 21. Pharmacological interventions for heart failure in people with chronic kidney disease.
    Lunney M; Ruospo M; Natale P; Quinn RR; Ronksley PE; Konstantinidis I; Palmer SC; Tonelli M; Strippoli GF; Ravani P
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012466. PubMed ID: 32103487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feature and impact of guideline-directed medication prescriptions for heart failure with reduced ejection fraction accompanied by chronic kidney disease.
    Chen YL; Hang CL; Su CH; Wu PJ; Chen HC; Fang HY; Fang YN; Cheng CI; Fu M; Chen SM
    Int J Med Sci; 2021; 18(12):2570-2580. PubMed ID: 34104088
    [No Abstract]   [Full Text] [Related]  

  • 23. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology.
    Mullens W; Martens P; Testani JM; Tang WHW; Skouri H; Verbrugge FH; Fudim M; Iacoviello M; Franke J; Flammer AJ; Palazzuoli A; Barragan PM; Thum T; Marcos MC; Miró Ò; Rossignol P; Metra M; Lassus J; Orso F; Jankowska EA; Chioncel O; Milicic D; Hill L; Seferovic P; Rosano G; Coats A; Damman K
    Eur J Heart Fail; 2022 Apr; 24(4):603-619. PubMed ID: 35239201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction.
    Tromp J; Ouwerkerk W; van Veldhuisen DJ; Hillege HL; Richards AM; van der Meer P; Anand IS; Lam CSP; Voors AA
    JACC Heart Fail; 2022 Feb; 10(2):73-84. PubMed ID: 34895860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sex differences in heart failure medications targeting the renin-angiotensin-aldosterone system.
    Nicolaou PA
    Eur J Pharmacol; 2021 Apr; 897():173961. PubMed ID: 33617824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
    Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-cardiac comorbidities in heart failure: an update on diagnostic and management strategies.
    Kodur N; Tang WHW
    Minerva Med; 2024 Jun; 115(3):337-353. PubMed ID: 38899946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
    Yang M; Butt JH; Kondo T; Jering KS; Docherty KF; Jhund PS; de Boer RA; Claggett BL; Desai AS; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Langkilde AM; Martinez FA; Petersson M; Shah SJ; Vaduganathan M; Wilderäng U; Solomon SD; McMurray JJV
    Eur J Heart Fail; 2022 Dec; 24(12):2307-2319. PubMed ID: 36342375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
    Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
    BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study.
    Blankenburg M; Fett AK; Eisenring S; Haas G; Gay A
    BMC Nephrol; 2019 May; 20(1):171. PubMed ID: 31096928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Experience of Angiotensin Receptor-Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease.
    Chang HY; Lin CC; Chao CJ; Lin YC; Wang YC; Liao CT; Huang JL; Lee YH; Huang CY; Chien LN; Hsu CY
    Mayo Clin Proc; 2023 Jan; 98(1):88-99. PubMed ID: 36109207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction.
    Vaduganathan M; Fonarow GC; Greene SJ; Devore AD; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J
    J Card Fail; 2022 Feb; 28(2):191-201. PubMed ID: 34428591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Practical management of worsening renal function in outpatients with heart failure and reduced ejection fraction: Statement from a panel of multidisciplinary experts and the Heart Failure Working Group of the French Society of Cardiology.
    Mewton N; Girerd N; Boffa JJ; Courivaud C; Isnard R; Juillard L; Lamblin N; Legrand M; Logeart D; Mariat C; Meune E; Sabouret P; Sebbag L; Rossignol P
    Arch Cardiovasc Dis; 2020 Oct; 113(10):660-670. PubMed ID: 32660835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The ability of modern therapy to improve the prognosis of patients with HF: role of angiotensin neprilysin inhibitors and sodium-glucose cotransporter inhibitors.
    Mareev YV; Mareev VY
    Kardiologiia; 2021 Jul; 61(6):4-10. PubMed ID: 34311683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacologic treatment of heart failure with reduced ejection fraction in chronic kidney disease].
    Heine GH; Rogacev KS
    Dtsch Med Wochenschr; 2019 Dec; 144(24):1714-1720. PubMed ID: 31791077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management.
    Beavers CJ
    Curr Cardiol Rep; 2022 Dec; 24(12):1785-1790. PubMed ID: 36272052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S; López-Mesa M; Gómez-Fernández P
    Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 36166243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.